- Home
- CAC vs CRGX Comparison
CAC vs CRGX Comparison
Compare CAC & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAC
- CRGX
- Stock Information
- Founded
- CAC 1875
- CRGX 2021
- Country
- CAC United States
- CRGX United States
- Employees
- CAC N/A
- CRGX N/A
- Industry
- CAC Major Banks
- CRGX
- Sector
- CAC Finance
- CRGX
- Exchange
- CAC Nasdaq
- CRGX Nasdaq
- Market Cap
- CAC N/A
- CRGX 621.4M
- IPO Year
- CAC 1997
- CRGX 2023
- Fundamental
- Price
- CAC $43.80
- CRGX $13.46
- Analyst Decision
- CAC Hold
- CRGX Strong Buy
- Analyst Count
- CAC 3
- CRGX 6
- Target Price
- CAC $46.67
- CRGX $31.80
- AVG Volume (30 Days)
- CAC 76.8K
- CRGX 231.3K
- Earning Date
- CAC 01-28-2025
- CRGX 03-20-2025
- Dividend Yield
- CAC 3.84%
- CRGX N/A
- EPS Growth
- CAC N/A
- CRGX N/A
- EPS
- CAC 3.20
- CRGX N/A
- Revenue
- CAC $168,756,000.00
- CRGX N/A
- Revenue This Year
- CAC N/A
- CRGX N/A
- Revenue Next Year
- CAC $30.91
- CRGX N/A
- P/E Ratio
- CAC $13.69
- CRGX N/A
- Revenue Growth
- CAC N/A
- CRGX N/A
- 52 Week Low
- CAC $28.62
- CRGX $10.91
- 52 Week High
- CAC $50.07
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- CAC 51.07
- CRGX 47.00
- Support Level
- CAC $43.09
- CRGX $12.51
- Resistance Level
- CAC $45.29
- CRGX $15.75
- Average True Range (ATR)
- CAC 1.01
- CRGX 1.09
- MACD
- CAC 0.25
- CRGX 0.17
- Stochastic Oscillator
- CAC 69.72
- CRGX 52.74
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.